Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Antoni Font Guiteras; Vincenza Conteduca; Daniel Wetterskog; M. T. A. Sharabiani; Enrique Grande; M. P. Fernandez Perez; Anuradha Jayaram; S. Salvi; Daniel Castellano; A. Romanel; C. Lolli; Valentina Casadio; Giorgia Gurioli; D. Amadori; S. Vazquez Estevez; Aránzazu González-del-Alba; B. Mellado; O. Fernandez Calvo; M. J. Méndez Vidal; Miguel Ángel Climent; Ignacio Durán; Ángel Rodríguez Sánchez; C. Santander; M. I. Sáez; J. Puente; D. Gasi Tandefelt; Anna Wingate; D. Dearnaley; F. Demichelis; Ugo De Giorgi; Enrique Gonzalez-Billalabeitia; Gerhardt Attard

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Antoni Font Guiteras, Vincenza Conteduca, Daniel Wetterskog, M. T. A. Sharabiani, Enrique Grande, M. P. Fernandez Perez, Anuradha Jayaram, S. Salvi, Daniel Castellano, A. Romanel, C. Lolli, Valentina Casadio, Giorgia Gurioli, D. Amadori, S. Vazquez Estevez, Aránzazu González-del-Alba, B. Mellado, O. Fernandez Calvo, M. J. Méndez Vidal, Miguel Ángel ClimentIgnacio Durán, Ángel Rodríguez Sánchez, C. Santander, M. I. Sáez, J. Puente, D. Gasi Tandefelt, Anna Wingate, D. Dearnaley, F. Demichelis, Ugo De Giorgi, Enrique Gonzalez-Billalabeitia, Gerhardt Attard

Research output: Contribution to journal › Article › Research › peer-review

243 Citations (Scopus)

Abstract

2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P¼0.004). There was no interaction between AR and docetaxel status (P¼0.83 for OS, P¼0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P<0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P<0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P¼0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. Conclusion: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. Clinical Trial number: NCT02288936 (PREMIERE trial).

Original language	English
Pages (from-to)	1508-1516
Number of pages	9
Journal	Annals of Oncology
Issue number	28
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Castration-resistant prostate cancer
Androgen receptor
Plasma DNA
Enzalutamide
Abiraterone
Biomarker

Access to Document

https://ddd.uab.cat/record/196494

Cite this

Font Guiteras, A., Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Vazquez Estevez, S., González-del-Alba, A., Mellado, B., Fernandez Calvo, O., Méndez Vidal, M. J., ... Attard, G. (2017). Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of Oncology, (28), 1508-1516. https://ddd.uab.cat/record/196494

@article{ac33b22b327540ca8f6caf543ebe0f0b,

title = "Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study",

abstract = "2632A>G (p.T878A)] were observed in eight (11\%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95\% CI 1.47-not reached; P¼0.004). There was no interaction between AR and docetaxel status (P¼0.83 for OS, P¼0.99 for PFS). In the PREMIERE trial, 11 patients (12\%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95\% CI 1.94-9.68; P<0.001), radiographic-PFS (rPFS) (HR 8.06; 95\% CI 3.26-19.93; P<0.001) and OS (HR 11.08; 95\% CI 2.16-56.95; P¼0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. Conclusion: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. Clinical Trial number: NCT02288936 (PREMIERE trial).",

keywords = "Castration-resistant prostate cancer, Androgen receptor, Plasma DNA, Enzalutamide, Abiraterone, Biomarker",

author = "\{Font Guiteras\}, Antoni and Vincenza Conteduca and Daniel Wetterskog and Sharabiani, \{M. T. A.\} and Enrique Grande and \{Fernandez Perez\}, \{M. P.\} and Anuradha Jayaram and S. Salvi and Daniel Castellano and A. Romanel and C. Lolli and Valentina Casadio and Giorgia Gurioli and D. Amadori and \{Vazquez Estevez\}, S. and Ar{\'a}nzazu Gonz{\'a}lez-del-Alba and B. Mellado and \{Fernandez Calvo\}, O. and \{M{\'e}ndez Vidal\}, \{M. J.\} and Climent, \{Miguel {\'A}ngel\} and Ignacio Dur{\'a}n and \{Rodr{\'i}guez S{\'a}nchez\}, {\'A}ngel and C. Santander and S{\'a}ez, \{M. I.\} and J. Puente and \{Gasi Tandefelt\}, D. and Anna Wingate and D. Dearnaley and F. Demichelis and \{De Giorgi\}, Ugo and Enrique Gonzalez-Billalabeitia and Gerhardt Attard",

year = "2017",

language = "English",

pages = "1508--1516",

number = "28",

}

Font Guiteras, A, Conteduca, V, Wetterskog, D, Sharabiani, MTA, Grande, E, Fernandez Perez, MP, Jayaram, A, Salvi, S, Castellano, D, Romanel, A, Lolli, C, Casadio, V, Gurioli, G, Amadori, D, Vazquez Estevez, S, González-del-Alba, A, Mellado, B, Fernandez Calvo, O, Méndez Vidal, MJ, Climent, MÁ, Durán, I, Rodríguez Sánchez, Á, Santander, C, Sáez, MI, Puente, J, Gasi Tandefelt, D, Wingate, A, Dearnaley, D, Demichelis, F, De Giorgi, U, Gonzalez-Billalabeitia, E & Attard, G 2017, 'Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study', Annals of Oncology, no. 28, pp. 1508-1516. <https://ddd.uab.cat/record/196494>

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. / Font Guiteras, Antoni; Conteduca, Vincenza; Wetterskog, Daniel et al.
In: Annals of Oncology, No. 28, 2017, p. 1508-1516.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

AU - Font Guiteras, Antoni

AU - Conteduca, Vincenza

AU - Wetterskog, Daniel

AU - Sharabiani, M. T. A.

AU - Grande, Enrique

AU - Fernandez Perez, M. P.

AU - Jayaram, Anuradha

AU - Salvi, S.

AU - Castellano, Daniel

AU - Romanel, A.

AU - Lolli, C.

AU - Casadio, Valentina

AU - Gurioli, Giorgia

AU - Amadori, D.

AU - Vazquez Estevez, S.

AU - González-del-Alba, Aránzazu

AU - Mellado, B.

AU - Fernandez Calvo, O.

AU - Méndez Vidal, M. J.

AU - Climent, Miguel Ángel

AU - Durán, Ignacio

AU - Rodríguez Sánchez, Ángel

AU - Santander, C.

AU - Sáez, M. I.

AU - Puente, J.

AU - Gasi Tandefelt, D.

AU - Wingate, Anna

AU - Dearnaley, D.

AU - Demichelis, F.

AU - De Giorgi, Ugo

AU - Gonzalez-Billalabeitia, Enrique

AU - Attard, Gerhardt

PY - 2017

Y1 - 2017

N2 - 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P¼0.004). There was no interaction between AR and docetaxel status (P¼0.83 for OS, P¼0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P<0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P<0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P¼0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. Conclusion: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. Clinical Trial number: NCT02288936 (PREMIERE trial).

AB - 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naı¨ve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P¼0.004). There was no interaction between AR and docetaxel status (P¼0.83 for OS, P¼0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P<0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P<0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P¼0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. Conclusion: Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. Clinical Trial number: NCT02288936 (PREMIERE trial).

KW - Castration-resistant prostate cancer

KW - Androgen receptor

KW - Plasma DNA

KW - Enzalutamide

KW - Abiraterone

KW - Biomarker

UR - https://www.scopus.com/pages/publications/85019315640

M3 - Article

SN - 0923-7534

SP - 1508

EP - 1516

JO - Annals of Oncology

JF - Annals of Oncology

IS - 28

ER -

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this